ID | TMAO: TMA | Total |
FMO3
|
PYROXD2
| Oxido-reductase | DMGDH interact | Rare & shared |
|---|
52 | 0.13 | 4 |  | †| §§ |  | § |
114 | 0.37 | 7 | †| §§ | § |  | §§* |
122 | 0.47 | 7 | ††| § | § |  | §§§ |
35 | 0.54 | 4 |  | ††|  |  | §§ |
99 | 0.58 | 7 | § | § |  | †| §§§§ |
64 | 0.61 | 3 | †| § |  |  | § |
62 | 0.79 | 4 |  | § | § |  | §§ |
113 | 0.79 | 3 | †|  |  |  | §* |
98 | 0.86 | 5 | ††| § |  | †| § |
56 | 0.87 | 5 | †| ††|  | †| § |
- Total = number of variants in all categories. †or § denotes the presence of a relevant allele in that category. Heterozygous = †, homozygous = §, hemizygous = *. FMO3 = variants in the FMO3 gene. PYROXD2 = variants in the PYROXD2 gene (see Table 3). Oxidoreductase = rare variants predicted to be deleterious in genes annotated for oxidoreductase function (similar pathway as FMO3). DMGDH interact = rare variants predicted to be deleterious in genes that are predicted to interact with DMGDH, a gene linked to similar symptoms as TMAU. Rare & shared = rare variants predicted to be deleterious that are shared between two subjects studied here (see Table 4). Table is ordered by TMAO:TMA ratios, starting with the most severely impaired subject
